News
Weight Loss In a Pill Will Make Eli Lilly a $1 Trillion Stock
Pharmaceutical giant Eli Lilly (LLY) surged 14% last week to $840 per share following positive Phase 3 trial results for its oral weight-loss drug, orforglipron. With a market cap of $796 billion, LLY is the world’s most valuable healthcare company, and its trajectory suggests it could reach $1,000 per share or more by year-end 2025.
Pharmacies told to stop making custom versions of Wegovy and Zepbound after shortages declared officially over ...
As the FDA cracks down on compounded GLP-1 drugs like semaglutide and tirzepatide, the market for GLP-1 supplements is taking ...
Less expensive versions of popular weight-loss medications like Wegovy and Zepbound are soon going to be taken off the market ...
U.S. regulators are trying to shut down the industry for compounded weight-loss drugs, which could result in higher costs or ...
Let's look at why this news could be a game-changer for Eli Lilly and its stock.
Pa., said Mounjaro changed his life with 'significant' health benefits. He's calling for widespread access to GLP-1 ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback